TriangleNCT01801436 · OUTCOME
Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Hour
- Interval / dispersion
- Standard Deviation
- Time frame
- 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
What was measured
The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.
Analysis population: PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.
Groups in this outcome
Bortezomib
Participants received 1.3 mg per m\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
| Group | Source count |
|---|---|
| Bortezomib | 10 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bortezomib | 88.74 | 58.38 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 58.38
- value
- 88.74
- denoms
- counts
- group Id
- OG000
- value
- 10
- units
- Participants
- description
- The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants received 1.3 mg per m\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
- id
- OG000
- title
- Bortezomib
- param Type
- MEAN
- population Description
- PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.
- reporting Status
- POSTED
- time Frame
- 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
- title
- Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1
- type
- PRIMARY
- unit Of Measure
- Hour
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice